Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.12
+0.52 (2.20%)
Mar 4, 2026, 4:00 PM EST - Market closed
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 31.86, with a low estimate of 19 and a high estimate of 36. The average target predicts an increase of 32.09% from the current stock price of 24.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $37 → $35 | Buy | Maintains | $37 → $35 | +45.11% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $34 → $35 | Strong Buy | Maintains | $34 → $35 | +45.11% | Feb 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $30 → $35 | Strong Buy | Maintains | $30 → $35 | +45.11% | Feb 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $34 | Strong Buy | Maintains | $30 → $34 | +40.96% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Maintains $31 → $36 | Strong Buy | Maintains | $31 → $36 | +49.25% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
505.67M
from 376.07M
Increased by 34.46%
Revenue Next Year
656.20M
from 505.67M
Increased by 29.77%
EPS This Year
0.32
from -0.13
EPS Next Year
1.20
from 0.32
Increased by 274.91%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 538.3M | 737.2M | |||
| Avg | 505.7M | 656.2M | |||
| Low | 478.2M | 611.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 43.1% | 45.8% | |||
| Avg | 34.5% | 29.8% | |||
| Low | 27.2% | 20.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.56 | 1.69 | |||
| Avg | 0.32 | 1.20 | |||
| Low | 0.08 | 0.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 428.1% | |||
| Avg | - | 274.9% | |||
| Low | - | 117.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.